ER positive: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 10:13, 17 March 2025
ER positive or Estrogen Receptor positive is a term used in oncology to describe cancer cells that have receptors (proteins) that bind estrogen, which can promote the growth of breast cancer cells. ER positive is the most common type of breast cancer, with about 80% of all breast cancers being ER positive.
Overview[edit]
Estrogen is a hormone that plays a role in the development and growth of female sexual characteristics. In some cases, estrogen can also promote the growth of certain types of cancer cells, such as breast cancer cells. The presence of estrogen receptors on these cells is what makes them ER positive.
Diagnosis[edit]
The diagnosis of ER positive breast cancer is made through a biopsy, where a sample of the tumor is examined under a microscope. The presence of estrogen receptors is determined through a process called immunohistochemistry.
Treatment[edit]
Treatment for ER positive breast cancer often involves hormone therapy, such as tamoxifen or aromatase inhibitors, which work by blocking the effects of estrogen on cancer cells. Other treatments may include surgery, radiation therapy, and chemotherapy.
Prognosis[edit]
The prognosis for ER positive breast cancer is generally good, as these cancers tend to grow more slowly and are more likely to respond to hormone therapy. However, the prognosis can vary depending on the stage of the cancer and other factors.
